KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non-Current Liabilities (2016 - 2025)

Sarepta Therapeutics has reported Other Non-Current Liabilities over the past 14 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 96.77% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 96.77%, while the annual FY2025 figure was $1.5 million, 96.77% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.5 million at Sarepta Therapeutics, up from $300000.0 in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $50.8 million in Q1 2021 and troughed at $300000.0 in Q3 2025.
  • A 5-year average of $37.7 million and a median of $43.6 million in 2021 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 395.71% in 2021 and later crashed 99.37% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $43.6 million in 2021, then fell by 15.37% to $36.9 million in 2022, then increased by 3.25% to $38.1 million in 2023, then grew by 24.41% to $47.4 million in 2024, then crashed by 96.77% to $1.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SRPT at $1.5 million in Q4 2025, $300000.0 in Q3 2025, and $47.4 million in Q2 2025.